REG - AstraZeneca PLC - Update on US review of Lynparza PROpel sNDA

AstraZenecaAnnouncement

15/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221215:nRSO7574Ja&default-theme=true

RNS Number : 7574J  AstraZeneca PLC  15 December 2022

15 December 2022 07:00 GMT

 

Update on US regulatory priority review of Lynparza in combination with

abiraterone in metastatic castration-resistant prostate cancer

 

AstraZeneca and MSD today announced that the US Food and Drug Administration
(FDA) has informed AstraZeneca that it will extend the Prescription Drug User
Fee Act (PDUFA) date by three months to provide further time for a full review
of the supplementary new drug application (sNDA) for Lynparza (olaparib) in
combination with abiraterone and prednisone or prednisolone for the treatment
of metastatic castration-resistant prostate cancer (mCRPC). The companies will
continue to work with the FDA to facilitate the completion of the agency's
review.

 

The sNDA is based on results from the pivotal PROpel Phase III trial,
(https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html)
which were published in June 2022 in NEJM Evidence.
(https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043) In August 2022, the
sNDA was granted Priority Review
(https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-granted-fda-priority-review-for-propel.html)
and AstraZeneca and MSD are committed to working with the FDA to bring this
treatment option to patients with mCRPC.

 

In November, the European Medicines Agency's Committee for Medicinal Products
for Human Use adopted a positive opinion
(https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer.html)
recommending approval of Lynparza in combination with abiraterone and
prednisone or prednisolone in the EU for the treatment of adult patients with
mCRPC for whom chemotherapy is not clinically indicated. This combination is
also undergoing regulatory reviews in other countries.

 

Lynparza is approved in the US based on results from the PROfound Phase III
trial
(https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html)
as monotherapy for patients with homologous recombination repair (HRR)
gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations) who have
progressed following prior treatment with enzalutamide or abiraterone; and in
the EU, Japan, and China for patients with BRCA-mutated mCRPC who have
progressed following prior therapy that included a new hormonal agent.

 

Notes

 

Metastatic castration-resistant prostate cancer

Metastatic prostate cancer is associated with a significant mortality
rate.(11) Development of prostate cancer is often driven by male sex hormones
called androgens, including testosterone.(12)

 

In patients with mCRPC, their prostate cancer grows and spreads to other parts
of the body despite the use of androgen-deprivation therapy to block the
action of male sex hormones.(6) Approximately 10-20% of men with advanced
prostate cancer will develop castration-resistant prostate cancer (CRPC)
within five years, and at least 84% of these men will have metastases at the
time of CRPC diagnosis.(6) Of patients with no metastases at CRPC diagnosis,
33% are likely to develop metastases within two years.(5)

 

Despite the advances in mCRPC treatment in the past decade with taxane and new
hormonal agent (NHA) treatment, there is high unmet need in this
population.(6,8,9,13)

 

PROpel

PROpel is a randomised, double-blind, multi-centre Phase III trial testing the
efficacy, safety, and tolerability of Lynparza versus placebo when given in
addition to abiraterone in men with mCRPC who had not received prior
chemotherapy or NHAs in the mCRPC setting.

 

Men in both treatment groups also received either prednisone or prednisolone
twice daily. The primary endpoint is investigator-assessed rPFS, with
sensitivity analyses by BICR, and secondary endpoints include overall
survival, time to secondary progression or death, time to first subsequent
therapy, and quality of life measures.

 

In the PROpel Phase III trial, Lynparza is combined with abiraterone, an NHA
which targets the androgen receptor (AR) pathway.

 

AR signalling engages a transcriptional programme that is critical for tumour
cell growth and survival in prostate cancer.(14,15) Preclinical models have
identified interactions between PARP signalling and the AR pathway which
support the observation of a combined anti-tumour effect of Lynparza and NHAs,
like abiraterone, in both HRR deficient and HRR proficient prostate
cancer.(16-18)

 

The PARP1 protein has been reported to be required for the transcriptional
activity of androgen receptors; therefore, inhibiting PARP with Lynparza may
impair the expression of androgen receptor target genes and enhance the
activity of NHAs.(14,17,19) Additionally, it is thought that abiraterone may
alter/inhibit the transcription of some HRR genes which may induce HRR
deficiency and increase sensitivity to PARP inhibition.(16,18,20,21)

 

For more information about the trial please visit ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT03732820) .

 

Lynparza

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted
treatment to block DNA damage response (DDR) in cells/tumours harbouring a
deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or
those where deficiency is induced by other agents (such as NHAs).

 

Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA
single-strand breaks, stalling of replication forks, their collapse and the
generation of DNA double-strand breaks and cancer cell death.

 

Lynparza is currently approved in a number of countries across multiple tumour
types including maintenance treatment of platinum-sensitive relapsed ovarian
cancer and as both monotherapy and in combination with bevacizumab for the
1st-line maintenance treatment of BRCA-mutated (BRCAm) and homologous
recombination repair deficient (HRD)-positive advanced ovarian cancer,
respectively; for gBRCAm, HER2-negative metastatic breast cancer (in the EU
and Japan this includes locally advanced breast cancer); for gBRCAm,
HER2-negative high-risk early breast cancer (in Japan this includes all BRCAm
HER2-negative high-risk early breast cancer); for gBRCAm metastatic pancreatic
cancer; and HRR gene-mutated metastatic castration-resistant prostate cancer
(BRCAm only in the EU and Japan). In China, Lynparza is approved for the
treatment of BRCA-mutated metastatic castration-resistant prostate cancer as
well as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian
cancer.

 

Lynparza, which is being jointly developed and commercialised by AstraZeneca
and MSD, has been used to treat over 75,000 patients worldwide. Lynparza has a
broad clinical trial development programme, and AstraZeneca and MSD are
working together to understand how it may affect multiple PARP-dependent
tumours as a monotherapy and in combination across multiple cancer types.
Lynparza is the foundation of AstraZeneca's industry-leading portfolio of
potential new medicines targeting DDR mechanisms in cancer cells.

 

The AstraZeneca and MSD strategic oncology collaboration

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known
as MSD outside the US and Canada, announced a global strategic oncology
collaboration to co-develop and co-commercialise Lynparza, the world's first
PARP inhibitor, and Koselugo (selumetinib), a mitogen-activated protein
kinase (MEK) inhibitor, for multiple cancer types.

 

Working together, the companies will develop Lynparza and Koselugo and other
potential new medicines as monotherapies and as combinations. The companies
will also develop Lynparza and Koselugo in combination with their respective
PD-L1 and PD-1 medicines independently.

 

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.    Cancer.org. Key Statistics for Prostate Cancer. Available at
https://www.cancer.org/cancer/prostate%20cancer/about/key-statistics.html
(https://www.cancer.org/cancer/prostate%20cancer/about/key-statistics.html) .
Accessed December 2022.

2.    Ng K, et al. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):
Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 2020;
8:209-230.

3.    Shore N, et al. Real-World Treatment Patterns and Overall Survival of
Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior
to PARP Inhibitors. Adv Ther. 2021;38:4520-4540.

4.    Wallis C, et al. Real-World Use of Androgen-Deprivation Therapy:
Intensification Among Older Canadian Men With de Novo Metastatic Prostate
Cancer. JNCI Cancer Spectr. 2021;5(6):pkab082.

5.    George D, et al. Treatment Patterns and Outcomes in Patients With
Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical
Practice Setting in the United States. Clin Genitourin Cancer. 2020
Aug;18(4):284-294.

6.    Kirby, M, et al. Characterising the Castration-Resistant Prostate
Cancer Population: a Systematic Review. Int J of Clin Pract.
2021;65(11):1180-1192.

7.    Smith MR, et al. Natural History of Rising Serum Prostate-Specific
Antigen in Men with Castrate Nonmetastatic Prostate Cancer. J Clin Oncol.
2005;23(13):2918-25.

8.    UroToday. What is Changing in Advanced Prostate Cancer? Available at
https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/122176-what-is-changing-in-advanced-prostate-cancer.html
(https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/122176-what-is-changing-in-advanced-prostate-cancer.html)
. Accessed December 2022.

9.    Liu J, et al. Second-line Hormonal Therapy for the Management of
Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using
a Claims Database. Sci Rep. 2020;10(1):4240.

10.   Mateo J, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate
Cancer. N Engl J Med. 2015;373:1697-1708.

11.   Chowdhury S, et al. Real-World Outcomes in First-Line Treatment of
Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Target Oncol. 2020;15(3):301-315.

12.   Cancer.Net. Prostate Cancer: Types of Treatment. Available at
https://www.cancer.net/cancer-types/prostate-cancer/types-treatment
(https://www.cancer.net/cancer-types/prostate-cancer/types-treatment) .
Accessed December 2022.

13.   UroToday. Beyond First-line Treatment of Metastatic Castrate-resistant
Prostate Cancer. Available at
https://www.urotoday.com/library-resources/mcrpc-treatment/114592-beyond-first-line
treatment-of-metastatic-castrate-resistant-prostate-cancer.html
(https://www.urotoday.com/library-resources/mcrpc-treatment/114592-beyond-first-line%20treatment-of-metastatic-castrate-resistant-prostate-cancer.html)
. Accessed December 2022

14.   Schiewer MJ, et al. Dual Roles of PARP-1 Promote Cancer Growth and
Progression. Cancer Discov. 2012;2(12):1134-1149.

15.   Schiewer MJ & Knudsen KE. AMPed up to treat prostate cancer: novel
AMPK activators emerge for cancer therapy. EMBO Mol Med. 2014;6(4):439-441.

16.   Li L, et al. Androgen Receptor Inhibitor-Induced "BRCAness" and PARP
Inhibition are Synthetically Lethal for Castration-Resistant Prostate Cancer.
Sci Signal. 2017; 10(480):eaam7479.

17.   Polkinghorn WR, et al. Androgen Receptor Signaling Regulates DNA
Repair in Prostate Cancers. Cancer Discov. 2013;3(11):1245-1253.

18.   Asim M, et al. Synthetic Lethality Between Androgen Receptor Signalling
and the PARP Pathway in Prostate Cancer. Nat Commun. 2017;8(1):374.

19.   Ju B-G, et al. A Topoisomerase IIbeta-Mediated dsDNA Break Required
for Regulated Transcription. Science. 2006;312(5781):1798-1802.

20.   Goodwin JF, et al. A Hormone-DNA Repair Circuit Governs the Response
to Genotoxic Insult. Cancer Discov. 2013;3(11):1254-1271.

21.   Tarish FL, et al. Castration Radiosensitizes Prostate Cancer Tissue by
Impairing DNA Double-Strand Break Repair. Sci Transl Med. 2015;7(312):312re11.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGMAPUPPGMC